TEVA Quote, Financials, Valuation and Earnings

Amicus Therapeutics has a net margin of -10.09% compared to Teva Pharmaceutical Industries's net margin of -4.76%. Teva Pharmaceutical Industries's return on equity of -13.27% beat Amicus Therapeutics's return on equity of -71.17%.

Teva Pharmaceutical Industries has a consensus price target of $24.06, signalling upside risk potential of 13.26%. On the other hand Amicus Therapeutics has an analysts' consensus of $17.33 which suggests that it could grow by 84.2%. Given that Amicus Therapeutics has higher upside potential than Teva Pharmaceutical Industries, analysts believe Amicus Therapeutics is more attractive than Teva Pharmaceutical Industries.

Teva Pharmaceutical Industries has a beta of 0.727, which suggesting that the stock is 27.272% less volatile than S&P 500. In comparison Amicus Therapeutics has a beta of 0.618, suggesting its less volatile than the S&P 500 by 38.193%.

Teva Pharmaceutical Industries has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Amicus Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Teva Pharmaceutical Industries pays -- of its earnings as a dividend. Amicus Therapeutics pays out -- of its earnings as a dividend.

Teva Pharmaceutical Industries quarterly revenues are $4.3B, which are larger than Amicus Therapeutics quarterly revenues of $141.5M. Teva Pharmaceutical Industries's net income of -$437M is lower than Amicus Therapeutics's net income of -$6.7M. Notably, Teva Pharmaceutical Industries's price-to-earnings ratio is -- while Amicus Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Teva Pharmaceutical Industries is 1.43x versus 5.78x for Amicus Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Novo Nordisk AS has a net margin of -10.09% compared to Teva Pharmaceutical Industries's net margin of 38.28%. Teva Pharmaceutical Industries's return on equity of -13.27% beat Novo Nordisk AS's return on equity of 88.95%.

Teva Pharmaceutical Industries has a consensus price target of $24.06, signalling upside risk potential of 13.26%. On the other hand Novo Nordisk AS has an analysts' consensus of $120.38 which suggests that it could grow by 37.34%. Given that Novo Nordisk AS has higher upside potential than Teva Pharmaceutical Industries, analysts believe Novo Nordisk AS is more attractive than Teva Pharmaceutical Industries.

Teva Pharmaceutical Industries has a beta of 0.727, which suggesting that the stock is 27.272% less volatile than S&P 500. In comparison Novo Nordisk AS has a beta of 0.447, suggesting its less volatile than the S&P 500 by 55.342%.

Teva Pharmaceutical Industries has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Novo Nordisk AS offers a yield of 1.65% to investors and pays a quarterly dividend of $0.52 per share. Teva Pharmaceutical Industries pays -- of its earnings as a dividend. Novo Nordisk AS pays out 37.96% of its earnings as a dividend. Novo Nordisk AS's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Teva Pharmaceutical Industries quarterly revenues are $4.3B, which are smaller than Novo Nordisk AS quarterly revenues of $10.5B. Teva Pharmaceutical Industries's net income of -$437M is lower than Novo Nordisk AS's net income of $4B. Notably, Teva Pharmaceutical Industries's price-to-earnings ratio is -- while Novo Nordisk AS's PE ratio is 28.40x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Teva Pharmaceutical Industries is 1.43x versus 9.95x for Novo Nordisk AS. Usually stocks with elevated PS ratios are considered overvalued.

Pfizer has a net margin of -10.09% compared to Teva Pharmaceutical Industries's net margin of 25.23%. Teva Pharmaceutical Industries's return on equity of -13.27% beat Pfizer's return on equity of 4.63%.

Teva Pharmaceutical Industries has a consensus price target of $24.06, signalling upside risk potential of 13.26%. On the other hand Pfizer has an analysts' consensus of $31.86 which suggests that it could grow by 19.83%. Given that Pfizer has higher upside potential than Teva Pharmaceutical Industries, analysts believe Pfizer is more attractive than Teva Pharmaceutical Industries.

Teva Pharmaceutical Industries has a beta of 0.727, which suggesting that the stock is 27.272% less volatile than S&P 500. In comparison Pfizer has a beta of 0.644, suggesting its less volatile than the S&P 500 by 35.588%.

Teva Pharmaceutical Industries has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pfizer offers a yield of 6.32% to investors and pays a quarterly dividend of $0.42 per share. Teva Pharmaceutical Industries pays -- of its earnings as a dividend. Pfizer pays out 436.39% of its earnings as a dividend.

Teva Pharmaceutical Industries quarterly revenues are $4.3B, which are smaller than Pfizer quarterly revenues of $17.7B. Teva Pharmaceutical Industries's net income of -$437M is lower than Pfizer's net income of $4.5B. Notably, Teva Pharmaceutical Industries's price-to-earnings ratio is -- while Pfizer's PE ratio is 35.93x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Teva Pharmaceutical Industries is 1.43x versus 2.55x for Pfizer. Usually stocks with elevated PS ratios are considered overvalued.

Sanofi SA has a net margin of -10.09% compared to Teva Pharmaceutical Industries's net margin of 19.88%. Teva Pharmaceutical Industries's return on equity of -13.27% beat Sanofi SA's return on equity of 5.8%.

Teva Pharmaceutical Industries has a consensus price target of $24.06, signalling upside risk potential of 13.26%. On the other hand Sanofi SA has an analysts' consensus of $63.06 which suggests that it could grow by 30.97%. Given that Sanofi SA has higher upside potential than Teva Pharmaceutical Industries, analysts believe Sanofi SA is more attractive than Teva Pharmaceutical Industries.

Teva Pharmaceutical Industries has a beta of 0.727, which suggesting that the stock is 27.272% less volatile than S&P 500. In comparison Sanofi SA has a beta of 0.576, suggesting its less volatile than the S&P 500 by 42.375%.

Teva Pharmaceutical Industries has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Sanofi SA offers a yield of 8.18% to investors and pays a quarterly dividend of $2.04 per share. Teva Pharmaceutical Industries pays -- of its earnings as a dividend. Sanofi SA pays out 82.48% of its earnings as a dividend. Sanofi SA's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Teva Pharmaceutical Industries quarterly revenues are $4.3B, which are smaller than Sanofi SA quarterly revenues of $15.6B. Teva Pharmaceutical Industries's net income of -$437M is lower than Sanofi SA's net income of $3.1B. Notably, Teva Pharmaceutical Industries's price-to-earnings ratio is -- while Sanofi SA's PE ratio is 24.40x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Teva Pharmaceutical Industries is 1.43x versus 2.27x for Sanofi SA. Usually stocks with elevated PS ratios are considered overvalued.